Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphoma. - Wikidata - awgldk - TriplyDB

Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphoma.

Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphoma.

http://www.wikidata.org/entity/Q39021479

about

Targeting histone methylation for cancer therapy: enzymes, inhibitors, biological activity and perspectives Targeting histone methyltransferases and demethylases in clinical trials for cancer therapy Targeting EZH2 in cancer Mammalian SWI/SNF chromatin remodeling complexes and cancer: Mechanistic insights gained from human genomics Synthesis of lysine methyltransferase inhibitors Polycomb Group (PcG) Proteins and Human Cancers: Multifaceted Functions and Therapeutic Implications The epigenetic basis of diffuse large B-cell lymphoma Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models Advances in sarcoma diagnostics and treatment Epigenetic modulators as therapeutic targets in prostate cancer EZH2 in Bladder Cancer, a Promising Therapeutic Target Epigenome-based personalized medicine in human cancer Epigenetic regulation of Keap1-Nrf2 signaling Diverse involvement of EZH2 in cancer epigenetics Mature aggressive B-cell lymphoma across age groups - molecular advances and therapeutic implications.Diffuse large B-cell lymphoma: can genomics improve treatment options for a curable cancer?Bone-in-culture array as a platform to model early-stage bone metastases and discover anti-metastasis therapies EZH2 alterations in follicular lymphoma: biological and clinical correlations.Role of EZH2 in cancer stem cells: from biological insight to a therapeutic target.Functional and therapeutic significance of EZH2 in urological cancers Regulation and Role of EZH2 in Cancer Synergistic Anti-Tumor Activity of EZH2 Inhibitors and Glucocorticoid Receptor Agonists in Models of Germinal Center Non-Hodgkin Lymphomas Selective inhibition of EZH2 and EZH1 enzymatic activity by a small molecule suppresses MLL-rearranged leukemia Chromatin Memory in the Development of Human Cancers Polycomb genes, miRNA, and their deregulation in B-cell malignancies Targeting histone methyltransferase EZH2 as cancer treatment.Histone methylases as novel drug targets: developing inhibitors of EZH2.Bioinformatics analysis of thousands of TCGA tumors to determine the involvement of epigenetic regulators in human cancer.Successful strategies in the discovery of small-molecule epigenetic modulators with anticancer potential.LATS2 Positively Regulates Polycomb Repressive Complex 2.Survival of skin cancer stem cells requires the Ezh2 polycomb group protein.Immunohistochemical and genomic profiles of diffuse large B-cell lymphomas: implications for targeted EZH2 inhibitor therapy?Discovery and Molecular Basis of a Diverse Set of Polycomb Repressive Complex 2 Inhibitors Recognition by EED.Targeting EZH2 and PRC2 dependence as novel anticancer therapy.Characterization of a Linked Jumonji Domain of the KDM5/JARID1 Family of Histone H3 Lysine 4 Demethylases.Chromatin deregulation in disease.Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy Targeting EZH2-mediated methylation of H3K27 inhibits proliferation and migration of Synovial Sarcoma in vitro Atypical teratoid/rhabdoid tumors-current concepts, advances in biology, and potential future therapies.

P2860

Q26744441-9DADF1FC-A2EC-4FB9-BBF3-34A3E37882AB Q26746038-86751260-609C-4ADF-9D27-BC78DC813B46 Q26769027-CF977CC0-A1C6-40A3-AD3D-B8327ABC6191 Q26776098-4F2700BE-DF99-4700-A41D-13FF82CCBEB4 Q26799953-A81A31BD-D3D5-4DB7-91A9-D4ADFA303B54 Q26801380-0F9D8805-7AC6-4B7E-B0F2-F092619E4629 Q26852288-3D7186F8-19E7-4B42-B51F-DC52A6C5634F Q27304386-2A05D9CF-C01C-41EA-BCFD-848C259C35FF Q27700259-3996E3A7-9A78-411F-BBE7-ADBFE2099D1B Q28069695-0533AEE9-8830-4A2E-9A08-061CAEB85870 Q28071912-77D16E61-8217-418D-B70E-6B347BA83170 Q28082054-41709C63-54F3-44BA-8495-9A8803925362 Q28083951-34EF1EDE-80DD-42CF-8DC7-B4E5F508F5A8 Q28084220-0DF6545A-C947-41AA-A4E1-A983F4484B65 Q28084911-E1833610-6C57-49A7-B7E0-A20EBE971D66 Q30240133-4D4CAA1A-67F7-4ECC-B80C-1ACE285D823E Q33622342-4FA6E66E-5C6C-44A4-B544-22285B10011B Q33628894-60FFFF6C-0992-4A00-801F-32608B807498 Q33701840-072F0A54-4A64-494A-B26C-8BF2CE602CFD Q33914216-6C61F06E-4071-4D1E-B99E-3ED5899895AD Q33914244-5DAE156C-EDD2-4A7D-8C04-87D69F85216F Q34043370-0E2A550F-CBA0-45E6-9CED-FA3B7C6398D8 Q34670913-7062A57F-372B-40A8-AE1F-DE455B8F6F36 Q34876825-8DFC09DE-2FAC-4F59-B514-FA38C0F1983F Q34979975-0D31CB8F-2F82-40BA-95A3-6DD227534499 Q35103527-602A2963-8AC3-4EAC-BA09-F3613AAAA001 Q35236465-AD70B634-2B70-4AC9-B40B-84328B815910 Q35510392-5C44AAE3-03E7-4D5C-AD4C-0788E8205133 Q35674363-5AEE290A-ACF8-4403-950C-3250819A3F1F Q35824823-3A91BE1D-70A6-40D1-8B43-01118B2CD8BF Q36081710-CFD800FF-4989-4895-9DCF-BEA9E644D6FC Q36087138-808AE0AB-600E-4FA4-BBFD-F95E59455745 Q36140942-0917FD7F-71E8-4958-B3AB-3EB0780C521D Q36245610-8FA92C39-FD30-453A-9972-945F5A23583B Q36445523-043A5A9C-C00B-4452-8E0B-22461AA60901 Q36548335-260B3085-F683-4364-9061-14C0F16CF52E Q36599581-B721B024-0FF4-4F1E-B6E5-C6326D78163A Q36653748-C9761E8B-1835-488A-8329-326EBEB7BDA9 Q36850467-02C2FAE9-285E-41D4-9A8D-C7A508D239A7 Q36893203-B350BA9D-7E59-400C-8259-1A4A87728E81

P2860

Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphoma.

http://www.wikidata.org/entity/Q39021479

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

2014年论文

@zh

2014年论文

@zh-cn

name

Selective inhibition of EZH2 b ...... 2-mutant non-Hodgkin lymphoma.

@en

Selective inhibition of EZH2 b ...... 2-mutant non-Hodgkin lymphoma.

@nl

type

label

Selective inhibition of EZH2 b ...... 2-mutant non-Hodgkin lymphoma.

@en

Selective inhibition of EZH2 b ...... 2-mutant non-Hodgkin lymphoma.

@nl

prefLabel

Selective inhibition of EZH2 b ...... 2-mutant non-Hodgkin lymphoma.

@en

Selective inhibition of EZH2 b ...... 2-mutant non-Hodgkin lymphoma.

@nl

P1433

Q39021479-B6474923-D456-42A1-815E-113B179576AF

P1476

Q39021479-C2D2E5C2-484F-4C05-82D0-560F1CC1A0E6

P2093

Q39021479-01812172-FBF2-4C08-BDAC-DD2B59D331D9

Q39021479-08AE3FD3-8314-49E9-830F-4CDB4F3C4A45

Q39021479-15675300-C5CD-437E-B46B-641B4506CC25

Q39021479-1740C664-A861-482E-95E4-A034345CCD64

Q39021479-1880A408-2167-47A5-88CF-0F18E4B31DBA

Q39021479-195450AF-71AF-4247-9B27-D4A2FED6F5C8

Q39021479-2AF03B0B-C97C-4328-8D6A-32619774779F

Q39021479-3B657A85-6116-4CB8-9431-276C64A6A1B1

Q39021479-3F06EE25-D870-40DB-8999-79C82FE21E99

Q39021479-3F1E2FFB-50D5-493F-853A-736026C89869

P304

Q39021479-8EA22CC7-2538-47FB-9219-9BD55015BE3F

P31

Q39021479-8AFE64EE-A72B-48B9-A7B0-910FB0C9FBAC

P356

Q39021479-254F072C-1448-45DA-ACD5-43C0FDDC5747

P433

Q39021479-37EB6FFD-3FF0-471B-B7AB-46FBE0BBAEE6

P478

Q39021479-318C67E2-0455-44C9-9A47-572F856EF5F6

P577

Q39021479-5C9BDE7A-57C4-4D68-817D-C3EDE538A10B

P698

Q39021479-537A9E12-6244-4DF6-8702-C56C2A976755

P356

1535-7163.MCT-13-0773

P1433

Molecular Cancer Therapeutics

P1476

Selective inhibition of EZH2 b ...... 2-mutant non-Hodgkin lymphoma.

@en

P2093

Akira Yokoi

http://www.w3.org/2001/XMLSchema#string

Alejandra Raimondi

http://www.w3.org/2001/XMLSchema#string

Christina J Allain

http://www.w3.org/2001/XMLSchema#string

Christine R Klaus

http://www.w3.org/2001/XMLSchema#string

Galina Kuznetsov

http://www.w3.org/2001/XMLSchema#string

Heike Keilhack

http://www.w3.org/2001/XMLSchema#string

Jesse J Smith

http://www.w3.org/2001/XMLSchema#string

Kevin W Kuntz

http://www.w3.org/2001/XMLSchema#string

Kuan-Chun Huang

http://www.w3.org/2001/XMLSchema#string

Mai Uesugi

http://www.w3.org/2001/XMLSchema#string

P304

842-854

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1535-7163.MCT-13-0773

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

13

http://www.w3.org/2001/XMLSchema#string

P577

2014-02-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24563539

http://www.w3.org/2001/XMLSchema#string